Pirfenidone regulates pericellular proteolysis in cancer

Files in this item
Date
2022Author
Krämer, Matthias
Advisors/Reviewers
Wygrecka, Malgorzata
Fugmann, Tim
Quotable link
http://dx.doi.org/10.22029/jlupub-5930Abstract
The orally available drug pirfenidone, which is approved for the therapy of idiopathic pulmonary fibrosis is inhibiting the proliferation and migration of lung cancer cells. This effects are partially mediated vie the regulation of the activity of the proteolytic system, especially via PAI-1.